How to Appeal a Keytruda (Pembrolizumab) Insurance Denial

A Keytruda denial usually means the insurer is questioning whether pembrolizumab fits its coverage criteria in your exact situation. That may involve the cancer type, the treatment line, biomarker results, prior therapies, or policy wording around medical necessity. The denial can feel especially maddening because Keytruda is so widely known, but coverage still depends on the specific clinical context.

This is one reason the denial letter matters so much. Some denials say the treatment is investigational. Others say criteria were not met or the request lacked enough documentation. Those reasons are not interchangeable, and the appeal needs to respond to the exact language the insurer used.

If a biomarker such as PD-L1 or MSI-high is part of why Keytruda is being recommended, that information often becomes central to the appeal. The more clearly the clinical rationale is documented, the stronger the file becomes.

A strong Keytruda appeal usually includes the denial letter, the pathology and biomarker findings supporting the use of pembrolizumab, clinic notes, and a letter of medical necessity from the oncologist. That letter should explain why Keytruda is appropriate in this disease, at this point in treatment, for this patient.

If the denial involves biomarker criteria, the appeal should be especially clear about those results. If PD-L1, MSI-high, tumor mutational burden, or another relevant marker is part of the case, it should be attached and cited plainly. If there are no relevant biomarkers, the oncologist should still explain the cancer-specific rationale for recommending pembrolizumab.

Ask the office whether a peer-to-peer review is appropriate. In some cases, a direct physician conversation can resolve the dispute faster than multiple written back-and-forth steps.

If the patient is symptomatic or treatment timing is urgent, ask whether the appeal can be expedited. That question matters because cancer treatment delay is not a neutral inconvenience. It can affect symptoms, progression risk, and the patient’s emotional state.

If the first appeal is denied, ask what the next review level is and whether external review is available. This is also a moment when oncology financial navigators and social workers can be helpful. They often know how the specific insurer tends to respond and what documentation usually strengthens the case.

A Keytruda denial can feel very personal because the drug often represents hope or a carefully chosen plan. But the appeal works best when it stays specific, organized, and evidence-based. The goal is not to persuade emotionally. It is to show that pembrolizumab fits the patient’s cancer and treatment setting medically.

The fastest way to strengthen the appeal is to ask what the insurer says is missing and how the oncology team wants to answer it. If pembrolizumab is tied to a biomarker, ask whether the report language is being included clearly enough in the request.

That helps turn a branded drug denial into a much more actionable file.

• What exact reason did the insurer give for denying Keytruda?
• Are the relevant biomarker or pathology results attached to the appeal?
• Should the oncologist request a peer-to-peer review?
• Can this appeal be expedited because treatment timing matters?